ArticlePloS one2026
MLND-IU: A multi-stage detection model of subcentimeter lung nodule with improved U-Net+.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To address the challenges of high miss rates in subcentimeter nodules, false positives caused by vascular adhesion, and insufficient multi-scale feature fusion in lung CT analysis, a multi-stage detection model named MLND-IU, which incorporates an improved U-Net++ architecture, is proposed. The three-stage framework begins with an enhanced RetinaNet optimized by a dynamic focal loss to generate candidate regions with high sensitivity while mitigating class imbalance. The second stage introduces AG-UNet++ with a novel Dense Attention Bridging Module (DABM), which employs a tensor product fusion of channel and deformable spatial attention across densely connected skip pathways to amplify feature representation for 3-5 mm nodules. The final stage employs a 3D Contextual Pyramid Module (3D-CPM) to integrate multi-slice morphological and contextual features, thereby reducing vascular false positives. Ablation studies indicated that the second stage improved the Dice coefficient by 21.1% compared with the first stage (paired t-test, p < 0.01, independent validation on LIDC-IDRI). The third stage further reduced the false positives per scan (FP/Scan) to 1.4, corresponding to an 87.3% reduction compared to the baseline. Multicenter validation on the LIDC-IDRI (n = 1,018) and DSB2017 (n = 1,595) datasets resulted in a segmentation Dice coefficient of 92.7%, a sensitivity of 93.4% for nodules smaller than 6 mm (compared to radiologists' sensitivity of 68.5%, p = 0.003), and an AUC of 0.84 for malignancy classification, representing a 19.2% improvement over conventional methods. With a processing time of 2.3 seconds per case, the proposed framework presents a clinically viable solution for early lung cancer screening by simultaneously improving small nodule detection and suppressing false positives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.